Business
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
SAN FRANCISCO, Nov. 9, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host a webcast analyst and investor conference call
About this update from Nektar Therapeutics
[{"type":"text","content":"SAN FRANCISCO, Nov. 9, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host a webcast analyst and investor conference call with a panel of oncology experts and company management on Wednesday, November 11, 2020, at 4:15 p.m. EST during the 2020 Society for Immunotherapy of Cancer Annual Meeting (SITC). The call will be hosted by Nektar management and will include SITC authors and presenters, Dr. Adi Diab, Associate Professor, Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center; Dr. Brendan Curti, Director of the Melanoma Program, Cytokine and Adoptive Immunotherapy and Genitourinary Oncology Research at Providence Cancer Institute; and Dr. Nina Shah, Associate Professor, Department of Medicine, at the University of California San Francisco.\nThe event will follow the SITC 2020 presentations on Wednesday which will include clinical data for three Nektar-sponsored studies, including updated clinical data from a cohort of first-line Stage IV metastatic melanoma patients in the PIVOT-02 study of bempegaldesleukin (NKTR-214; BEMPEG) with nivolumab, as well as presentations about Nektar's NKTR-255 and NKTR-262 programs. The 2020 SITC Annual Meeting is being held virtually from November 9 to November 14, 2020.\nAnalyst Call with Panel of Oncologists:\nDate and Time: Wednesday, November 11, 2020, at 4:15 p.m. EST\nDial-in: 877-881-2183 (toll-free) or 970-315-0453 (enter access code 2090614)\nInvestors and analysts can also view slides and listen to the live audio webcast of the presentation at https://edge.media-server.com/mmc/p/25u4g5o7. The event will also be available for replay for two weeks on the company's website, www.nektar.com.\nDetails of the presentations at SITC are as follows:\nNektar Oral and Poster Presentations at SITC\nAbstract 355: \"First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies\", Shah, N., et al.\nPoster will be available on November 9th at 8:00 AM EST Poster Session Date and Time: Wednesday, November 11th, 2020, from 5:15 p.m. - 5:45 p.m. ESTAbstract 368: \"REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors\", Diab, A., et al.\nOral Session Title: Combinato...